SER
Price
$5.94
Change
-$0.20 (-3.26%)
Updated
Jul 3 closing price
Capitalization
59.21M
XTLB
Price
$1.32
Change
+$0.12 (+10.00%)
Updated
Jul 3 closing price
Capitalization
9.73M
Interact to see
Advertisement

SER vs XTLB

Header iconSER vs XTLB Comparison
Open Charts SER vs XTLBBanner chart's image
Serina Therapeutics
Price$5.94
Change-$0.20 (-3.26%)
Volume$1.15K
Capitalization59.21M
XTL Biopharmaceuticals
Price$1.32
Change+$0.12 (+10.00%)
Volume$43.81K
Capitalization9.73M
SER vs XTLB Comparison Chart in %
Loading...
SER
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XTLB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SER vs. XTLB commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SER is a Hold and XTLB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (SER: $5.94 vs. XTLB: $1.32)
Brand notoriety: SER and XTLB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SER: 9% vs. XTLB: 108%
Market capitalization -- SER: $59.21M vs. XTLB: $9.73M
SER [@Biotechnology] is valued at $59.21M. XTLB’s [@Biotechnology] market capitalization is $9.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SER’s FA Score shows that 0 FA rating(s) are green whileXTLB’s FA Score has 0 green FA rating(s).

  • SER’s FA Score: 0 green, 5 red.
  • XTLB’s FA Score: 0 green, 5 red.
According to our system of comparison, XTLB is a better buy in the long-term than SER.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SER’s TA Score shows that 6 TA indicator(s) are bullish while XTLB’s TA Score has 6 bullish TA indicator(s).

  • SER’s TA Score: 6 bullish, 2 bearish.
  • XTLB’s TA Score: 6 bullish, 0 bearish.
According to our system of comparison, XTLB is a better buy in the short-term than SER.

Price Growth

SER (@Biotechnology) experienced а -3.10% price change this week, while XTLB (@Biotechnology) price change was +11.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

SER is expected to report earnings on May 08, 2025.

XTLB is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SER($59.2M) has a higher market cap than XTLB($9.73M). SER YTD gains are higher at: 18.563 vs. XTLB (-34.841). XTLB has higher annual earnings (EBITDA): 630K vs. SER (-488K). SER has more cash in the bank: 4.27M vs. XTLB (133K). SER (0) and XTLB (0) have equivalent revenues.
SERXTLBSER / XTLB
Capitalization59.2M9.73M608%
EBITDA-488K630K-77%
Gain YTD18.563-34.841-53%
P/E Ratio1.76N/A-
Revenue00-
Total Cash4.27M133K3,208%
Total Debt227KN/A-
FUNDAMENTALS RATINGS
SER vs XTLB: Fundamental Ratings
SER
XTLB
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
43
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10093
PRICE GROWTH RATING
1..100
5563
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XTLB's Valuation (43) in the Biotechnology industry is somewhat better than the same rating for SER (83) in the null industry. This means that XTLB’s stock grew somewhat faster than SER’s over the last 12 months.

XTLB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SER (100) in the null industry. This means that XTLB’s stock grew similarly to SER’s over the last 12 months.

XTLB's SMR Rating (93) in the Biotechnology industry is in the same range as SER (100) in the null industry. This means that XTLB’s stock grew similarly to SER’s over the last 12 months.

SER's Price Growth Rating (55) in the null industry is in the same range as XTLB (63) in the Biotechnology industry. This means that SER’s stock grew similarly to XTLB’s over the last 12 months.

SER's P/E Growth Rating (100) in the null industry is in the same range as XTLB (100) in the Biotechnology industry. This means that SER’s stock grew similarly to XTLB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SERXTLB
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
76%
Momentum
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
76%
MACD
ODDS (%)
Bullish Trend 4 days ago
88%
Bullish Trend 4 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
81%
Advances
ODDS (%)
N/A
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
N/A
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
85%
Aroon
ODDS (%)
Bullish Trend 4 days ago
85%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
SER
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XTLB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CMBM0.420.02
+5.11%
Cambium Networks Corp
TCBI85.851.59
+1.89%
Texas Capital Bancshares
PLPC169.292.21
+1.32%
Preformed Line Products Company
SGD0.78N/A
+0.38%
Safe and Green Development Corporation
PHG24.17-0.35
-1.43%
Koninklijke Philips NV

SER and

Correlation & Price change

A.I.dvisor indicates that over the last year, SER has been closely correlated with LIANY. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if SER jumps, then LIANY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SER
1D Price
Change %
SER100%
-3.26%
LIANY - SER
69%
Closely correlated
+3.17%
GERN - SER
65%
Loosely correlated
+2.14%
XTLB - SER
59%
Loosely correlated
+10.00%
ELVN - SER
37%
Loosely correlated
+0.44%
TOVX - SER
34%
Loosely correlated
-1.56%
More

XTLB and

Correlation & Price change

A.I.dvisor indicates that over the last year, XTLB has been loosely correlated with SER. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XTLB jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XTLB
1D Price
Change %
XTLB100%
+10.00%
SER - XTLB
59%
Loosely correlated
-3.26%
UNCY - XTLB
28%
Poorly correlated
-0.86%
BCLI - XTLB
27%
Poorly correlated
-0.85%
ADTX - XTLB
27%
Poorly correlated
-1.60%
ANRO - XTLB
26%
Poorly correlated
+2.17%
More